Capital Research Global Investors Has $95.93 Million Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)

Capital Research Global Investors raised its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 0.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,537,341 shares of the company’s stock after acquiring an additional 6,891 shares during the quarter. Capital Research Global Investors owned approximately 6.18% of Structure Therapeutics worth $95,933,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in GPCR. Capital International Investors increased its position in Structure Therapeutics by 6.8% in the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company’s stock worth $43,909,000 after purchasing an additional 103,059 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Structure Therapeutics by 45.1% in the fourth quarter. Principal Financial Group Inc. now owns 791,134 shares of the company’s stock valued at $21,456,000 after purchasing an additional 245,775 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Structure Therapeutics by 4.5% during the 4th quarter. Franklin Resources Inc. now owns 738,090 shares of the company’s stock worth $20,017,000 after buying an additional 31,984 shares during the period. American Century Companies Inc. raised its holdings in Structure Therapeutics by 12.3% in the 4th quarter. American Century Companies Inc. now owns 612,616 shares of the company’s stock worth $16,614,000 after acquiring an additional 67,325 shares during the period. Finally, Marshall Wace LLP lifted its position in Structure Therapeutics by 339.6% during the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company’s stock worth $15,817,000 after acquiring an additional 450,531 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Trading Up 17.4 %

Shares of NASDAQ:GPCR opened at $21.76 on Monday. The firm has a market capitalization of $1.25 billion, a PE ratio of -29.41 and a beta of -1.35. The business’s 50 day moving average is $20.23 and its 200-day moving average is $28.31. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. On average, sell-side analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.